Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lang Wenwang, Wang Jiangbo, Zhao Haiqing, He Yulong, Jiang Qinling, Ai Qi, Ouyang Ming
Аннотация
PURPOSE: Socazolimab, in combination with chemotherapy, has been shown to prolong progression-free survival (PFS) and overall survival (OS) compared with chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). This study is the first to evaluate its cost-effectiveness from the perspectives of both the U.S. payer and Chinese healthcare systems.
METHODS: A Markov state-transition model was employed to conduct an economic evaluation, incorporating clinical and economic parameters from both the U.S. and China. Baseline patient characteristics and key clinical inputs were sourced from a randomized phase 3 trial, whereas cost and utility values were derived from open-access databases and published literature. The primary outcomes assessed included quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). Model uncertainty was addressed through probabilistic sensitivity, one-way sensitivity, and scenario analyses.
RESULTS: In the base-case scenario, the addition of socazolimab to chemotherapy resulted in a marginal QALY gain of 0.09, at an incremental cost of $14,504.53, leading to an ICER of $152,228.60 per QALY. This ICER was below China's willingness-to-pay (WTP) threshold of $40,354.27 per QALY, making it not cost-effective, with an INHB of -0.26 QALYs and an INMB of -$10,523.93. In the U.S., while the incremental QALY gain remained at 0.10, the additional cost increased to $85,599.55, yielding an ICER of $878,912.80 per QALY, far exceeding that of the U.S. WTP threshold of $150,000.00, confirming its lack of cost-effectiveness.
CONCLUSIONS: The combination of socazolimab with chemotherapy is not a cost-effective first-line treatment option for ES-SCLC in either China or the United States, highlighting the need for price adjustments and alternative treatment strategies to improve economic viability.
METHODS: A Markov state-transition model was employed to conduct an economic evaluation, incorporating clinical and economic parameters from both the U.S. and China. Baseline patient characteristics and key clinical inputs were sourced from a randomized phase 3 trial, whereas cost and utility values were derived from open-access databases and published literature. The primary outcomes assessed included quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). Model uncertainty was addressed through probabilistic sensitivity, one-way sensitivity, and scenario analyses.
RESULTS: In the base-case scenario, the addition of socazolimab to chemotherapy resulted in a marginal QALY gain of 0.09, at an incremental cost of $14,504.53, leading to an ICER of $152,228.60 per QALY. This ICER was below China's willingness-to-pay (WTP) threshold of $40,354.27 per QALY, making it not cost-effective, with an INHB of -0.26 QALYs and an INMB of -$10,523.93. In the U.S., while the incremental QALY gain remained at 0.10, the additional cost increased to $85,599.55, yielding an ICER of $878,912.80 per QALY, far exceeding that of the U.S. WTP threshold of $150,000.00, confirming its lack of cost-effectiveness.
CONCLUSIONS: The combination of socazolimab with chemotherapy is not a cost-effective first-line treatment option for ES-SCLC in either China or the United States, highlighting the need for price adjustments and alternative treatment strategies to improve economic viability.